Meridian Clinical Research Holds Fourth Annual Physician Training Meeting

Meridian Clinical Research held its largest ever Annual Physician Training Meeting July 12-14, 2018 in Cancun, Mexico. More than 150 attended the event, including 50 principal investigators and sub-investigators. Physicians from all 18 Meridian sites attended, along with representatives from each of Platinum Research Network’s seven companies.

“It provides us an opportunity to share with investigators how we are preparing for, and shaping the future of clinical research,” said Greg Adams, director clinical management at Pfizer. Adams, who spoke and fielded questions at the event, also said the meeting served as a platform to share expectations and explore ideas for current trial conduct.

“I hope to see more of this kind of collaboration in the industry,” said Lynlee Burton, director of project delivery for vaccines at PRA Health Sciences. “It ultimately improves the patient experience by engaging everyone involved in the delivery of care in a clinical research setting. As we develop more efficient strategies to conduct high-quality research, events like this help us implement those strategies more quickly at the site level.”

While the state of vaccine research was discussed, specialists across numerous therapeutic domains — including neurology, urology, immunology, and dermatology — participated in the event.

“We’re grateful that presenters like Greg and Lynlee are so eager to help educate our sites and physicians,” said Nicole Osborn, founder and CEO of Meridian. “The meeting strengthens relationships with our principal investigators and connects them to the companies and people that direct clinical trials.”

To learn more about Meridian, visit mcrmed.com or schedule a meeting with a Meridian representative at an upcoming event, such as the 2018 Global Site Solutions Summit, World Vaccine Congress Europe, or the CNS Summit 2018.

About Meridian Clinical Research

Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new pharmaceutical drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is headquartered at a dedicated research center in Omaha, NE, and conducts Phase 1-4 studies at 18 investigative sites across North America. Meridian supports research across numerous therapeutic areas and specializes in high-volume vaccine trials. For more information, visit www.mcrmed.com.